Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine... Show more
Cardio Diagnostics Holdings, Inc. (CDIO) is a U.S.-listed healthcare company that develops and commercializes precision molecular tests for cardiovascular disease. Rather than treating heart disease, the company aims to help clinicians detect it earlier and assess risk more precisely using a routine blood draw. Investors follow CDIO because it sits at the intersection of two long-running trends: the rising burden of cardiovascular disease and the broader shift toward personalized, data-driven medicine.
Cardio Diagnostics was founded in 2017 and is headquartered in Chicago, Illinois. The company became publicly traded on the Nasdaq in October 2022 through a business combination with a special purpose acquisition company (SPAC), Mana Capital Acquisition Corp., under which the legacy operating business became a wholly owned subsidiary. As a smaller reporting company, it operates with a relatively small team and remains in an early phase of commercialization.
The company's business model centers on proprietary, blood-based tests that combine epigenetic and genetic analysis. Epigenetics refers to chemical changes — such as DNA methylation — that affect how genes are expressed without altering the underlying DNA sequence. Cardio Diagnostics' flagship products include:
The company's underlying technology is licensed from the University of Iowa Research Foundation. Its tests are marketed to telemedicine providers, concierge and longevity clinics, risk-bearing provider organizations, and employer organizations. A key element of the company's market position is its emphasis on accessibility: by using a standard blood sample, it seeks to offer advanced cardiovascular risk assessment beyond traditional cholesterol and imaging-based approaches.
Financially, Cardio Diagnostics is pre-profit and generates only minimal revenue. As an emerging growth company, it continues to invest in test validation, laboratory infrastructure, and commercialization, and it has historically funded operations through equity financing.
Investor interest in CDIO is largely thematic. Cardiovascular disease is among the leading causes of death globally, creating a large potential market for earlier and more accurate detection tools. Cardio Diagnostics' epigenetic approach is differentiated from conventional risk calculators and lipid panels, offering the possibility of a more personalized risk profile. The company has also taken steps to build in-house laboratory capacity, including a CLIA-certified facility in Iowa City, Iowa, which it says gives it end-to-end control over test processing.
Beyond its core tests, the company's data and software assets — such as the HeartRisk platform and Actionable Clinical Intelligence — point toward a broader ambition of building a cardiovascular-focused precision medicine ecosystem. Coverage announcements from provider networks are also a signal investors watch, since reimbursement and payer adoption are critical to the company's long-term commercial prospects.
Investing in CDIO carries substantial risks typical of early-stage diagnostics companies. The business generates limited revenue and has reported operating losses, meaning it may require additional capital to fund operations and growth. Its future depends heavily on gaining regulatory clearances, securing reimbursement, and convincing providers to adopt its tests at scale.
The company operates in a competitive healthcare landscape that includes established diagnostics firms, traditional cardiovascular risk assessment tools, and emerging precision medicine players. There is also technology and regulatory risk: new tests must demonstrate clinical utility, and changes in reimbursement policy or laboratory regulations could affect demand. Finally, as a small-cap stock with a limited share float and a history of equity raises, CDIO may exhibit significant price volatility and dilution risk.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. The tool allows users to efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to see how it can support your research process.
Cardio Diagnostics Holdings offers a distinctive, science-driven approach to cardiovascular care through epigenetic and genetic blood testing, positioned within the large and growing field of precision diagnostics. Its company overview and business model reflect both meaningful ambition and the realities of an early-stage firm still working toward commercial scale and profitability. For investors, CDIO represents a high-risk, high-uncertainty exposure to an emerging corner of the healthcare market — one whose long-term relevance will depend on clinical adoption, reimbursement, and execution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology